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A B S T R A C T
Objective: To test whether maternal hemoglobin during pregnancy associates with offspring perinatal
outcomes in a developed country. Changes in maternal hemoglobin concentration during pregnancy are
partly physiological phenomena reflecting alterations of maternal blood volume. Especially hemoglobin
measures outside the physiological range may influence maternal health and fetal growth with long-
lasting consequences.
Study design: We studied an unselected sample drawn from two regional birth cohorts born 20 years
apart: The Northern Finland Birth Cohorts 1966 and 1986. These are two mother-and-child population-
based birth cohorts together comprising 21,710 mothers and their children. After exclusions, the sample
size of the current study was 20,554. Concentrations of maternal hemoglobin at first and last antenatal
visits were categorized as low (lowest 10%), medium (reference) or high (highest 10%). Multinomial
logistic regression analyses for categories of maternal hemoglobin and perinatal outcomes such as
preterm delivery and full-term small and large for gestational age were conducted with adjustments for
maternal cofactors.
Results: Low maternal hemoglobin at early pregnancy associated with decreased risk of full-term small
for gestational age (adjusted OR 0.73, 95% CI [0.58, 0.93], p = 0.010). At late pregnancy, low maternal
hemoglobin associated with increased risk of preterm delivery (adjusted OR 1.60, 95% CI [1.26, 2.02],
p < 0.0005) whereas high maternal hemoglobin associated with increased risk of full-term small for
gestational age (adjusted OR 1.29, 95% CI [1.07, 1.56], p = 0.009). Maternal hemoglobin did not show
constant association with risk of large for gestational age.
Conclusion: The results from this study support evidence that both low and high maternal hemoglobin
associate with adverse perinatal outcomes. Low maternal hemoglobin associated with preterm delivery
and high with full-term small for gestational age. Association was mainly present when maternal
hemoglobin was measured during the third trimester. These results indicate that it is important to
monitor both extremes of maternal hemoglobin throughout the pregnancy.
© 2019 Elsevier B.V. All rights reserved.
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Both low and high maternal hemoglobin (mHb) concentration
has been consistently associated with adverse perinatal outcomes
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own data with later developmental indices [8]. Low hemoglobin
and anemia (generally defined as mHb < 110 g/l) are global
problems affecting both the mother and the developing child. In
2011, the global prevalence of anemia among pregnant women was
38%, which translated to 32 million mothers [9]. Regionally, the
prevalence of maternal anemia vary substantially from 22% in
European and North American countries to 56% in Central and
West Africa [10].
Several environmental and behavioral maternal factors affect
mHb and the developing child. Smoking during pregnancy has
been associated with placental defects, prematurity and growth
restriction (reviewed in [11]). Furthermore, smoking associates
with increased mHb levels, which may contribute to increased risk
of adverse perinatal outcomes [7,12]. Low maternal BMI is
associated with increased risk of spontaneous preterm birth
whereas some studies report obesity to have a protective effect
[13]. However, obese mothers are in risk for hypertensive
disorders, which associate with increased risk of medically
indicated preterm birth [13]. Mother’s low education was
associated with prematurity and small for gestational age (SGA)
in recent meta-analysis comprising of 12 European countries,
although there were differences between countries [14]. Nullipa-
rous mothers are at increased risk of preterm delivery and SGATable 1
Characteristics of mothers and singleton newborns in the pooled sample and stratified
Pooled 
Early maternal hemoglobin 
Reference, n (%) 15248 (80.4) 
Low, n (%) 1888 (10.0) 
High, n (%) 1817 (9.6) 
Late maternal hemoglobin 
Reference, n (%) 16096 (80.3) 
Low, n (%) 1978 (9.9) 
High, n (%) 1961 (9.8) 
Mean maternal age, years (SD) 27.8 (6.2) 
Mean pre-pregnancy BMI, kg/m2 (SD) 22.8 (3.4) 
Maternal smoking 
No, n (%) 15581 (76.9) 
Yes, but stopped, n (%) 986 (4.9) 
Yes, n (%) 3701 (18.3) 
Maternal SES 
Professional, n (%) 3697 (18.4) 
Skilled worker, n (%) 5981 (29.7) 
Unskilled worker, n (%) 3539 (17.6) 
Housewife, n (%) 6906 (34.3) 
Parity 
First child, n (%) 6813 (33.2) 
Second or later child, n (%) 13712 (66.8) 
Maternal hypertensive disorders 
Normotensive, n (%) 13535 (83) 
Gestational hypertension, n (%) 1253 (7.7) 
Pre-eclampsia, n (%) 423 (2.6) 
Chronic hypertension, n (%) 881 (5.4) 
Superimposed pre-eclampsia, n (%) 208 (1.3) 
Mean birth weight, grams (SD) 3518 (556) 
Mean gestational age, weeks (SD) 39.9 (1.9) 
Boys, n (%) 10529 (51.2) 
Preterm delivery, n (%) 1003 (5.0) 
Full-term SGA, n (%) 1746 (9.2) 
Full-term LGA, n (%) 1773 (9.4) 
* Comparison between NFBC1966 and NFBC1986.
A p < 0.05 between all mHb categories.
B p < 0.05 between all SES categories except professional vs. skilled worker.
C p < 0.05 between all hypertensive disorder categories except normotensive vs. super
eclampsia vs. superimposed pre-eclampsia.specifically if the mother is under 18 years old and maternal age 35
or more is associated with increased risk of SGA but not
prematurity [15].
In the current study, we study the association between mHb
and adverse perinatal outcomes within two study populations
located in Finland. These populations are highly homogenous
due to standardized antenatal care and pregnancy counselling,
which contributes to fewer environmental confounders than in
more diverse settings. Association between mHb at different
time points of pregnancy and such outcomes as prematurity
and small and large for gestational age (SGA and LGA) are
studied.
Material and methods
Inclusion and exclusion criteria
The study population is the mothers and children of Northern
Finland Birth Cohorts (NFBC) 1966 and 1986 which are population-
based birth cohorts comprising 98% (n = 21,710) of all deliveries
occurred in 1966 and 1985-86 in Oulu and Lapland provinces of
Finland. Multiple pregnancies, individuals without both early and
late mHb measurements and individuals with mHb over 5 SD from
mean (n = 1,156) were excluded from the analyses resulting in final by the cohort.
NFBC1966 NFBC1986 p value *
< 0.0005 A
8348 (83.7) 6900 (76.8)
827 (8.3) 1061 (11.8)
798 (8.0) 1019 (11.3)
< 0.0005 A
9118 (81.4) 6978 (76.0)
926 (8.3) 1052 (11.9)
1153 (10.3) 808 (9.1)
27.8 (6.7) 27.8 (5.5) 0.911
23.1 (3.2) 22.4 (3.5) < 0.0005
< 0.0005 A
8827 (78.1) 6754 (75.4)
753 (6.7) 233 (2.6)
1728 (15.3) 1973 (22)
< 0.0005 B
1435 (12.6) 2262 (25.9)
2469 (21.7) 3512 (40.2)
985 (8.7) 2554 (29.2)
6497 (57.1) 409 (4.7)
0.076
3770 (32.7) 3043 (33.9)
7768 (67.3) 5944 (66.1)
< 0.0005 C
6460 (76.3) 7075 (90.3)
983 (11.6) 270 (3.4)
241 (2.8) 182 (2.3)
668 (7.9) 213 (2.7)
116 (1.4) 92 (1.2)
3478 (560) 3570 (546) < 0.0005
40.0 (2.1) 39.8 (1.7) < 0.0005
5917 (51.2) 4612 (51.3) 0.978
610 (5.5) 393 (4.5) 0.002
1172 (11.1) 574 (6.9) < 0.0005
908 (8.6) 865 (10.3) < 0.0005
imposed pre-eclampsia, gestational hypertension vs. chronic hypertension and pre-
46 J. Ronkainen et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 238 (2019) 44–48sample size of 20,554. Concentration of mHb at early pregnancy
was available from 18,953 mothers and at late pregnancy from
20,035 mothers. Informed consent was obtained from study
subjects for the use of their data in the study. Approval for the
studies was granted by the ethics committee of the Northern
Ostrobothnia Hospital District in Oulu, Finland in accordance with
the declaration of Helsinki.
Predictor variables
Mean gestational week for early mHb measurement was 13.3
(SD 4.8) and for late mHb 38.2 (SD 3.4). In NFBC1966, mHb was
measured with Tallquist chart, hemometer or photometer and in
NFBC1986, with standard photometer. In NFBC1966, mHb was first
standardized for measurement method and then mHb measures
were transformed to z values [z(mHb)=(mHb-mean(mHb))/SD
(mHb)] separately for each cohort and pregnancy time point. Z
value of mHb below 10th percentile was defined as low and above
90th percentile as high mHb while the middle 80% was used as
reference.
Perinatal outcomes
Children born before 37 weeks of gestation were defined as
preterm. SGA and LGA were analyzed from full-term children
(gestational age 37 weeks or more) only. SGA was defined as below
10th percentile and LGA as above 90th percentile of the Finnish
national reference according to [16].
Covariates
Following factors were used as covariates in the statistical
models: maternal smoking, maternal hypertensive disorders,
maternal pre-pregnancy body mass index (BMI), maternal
socioeconomic status (SES), parity and maternal age. Maternal
smoking was categorized as not smoked during pregnancy
(reference, n = 15,581), smoked, but not after second month of
pregnancy (n = 986) and smoked after second month of
pregnancy (n = 3,701). Maternal hypertensive disorders were
defined as described in [17]: Normotensive (reference,
n = 13,535), gestational hypertension (n = 1,253), pre-eclampsia
(n = 423), chronic hypertension (n = 881) and superimposed pre-
eclampsia (n = 208). Maternal SES was categorized as profes-
sionals (reference, n = 3,697), skilled workers (n = 5,981), un-
skilled workers (n = 3,539) and housewives, farmers and
farmer’s wives (n = 6,906). Parity was dichotomized as nullipa-
rous (reference, n = 6,813) and multiparous (n = 13,712). Mater-
nal pre-pregnancy BMI (weight in kg/(height in m)2) and age
were used as continuous variables. Cohort was included in the
models, NFBC1966 as a reference (n = 11,554) and NFBC1986
(n = 9,000). Sex of the child was not included in the models
because it did not associate with prematurity in the currentTable 2
Association between maternal hemoglobin during pregnancy and preterm delivery. OR
significant when p < 0.0125.
Base model Mod
Outcome mHb OR 95% CI p OR 
Preterm Low early 1.17 [0.94, 1.44] 0.157 1.23
delivery High early 1.12 [0.90, 1.39] 0.323 1.10
Low late 1.58 [1.29, 1.93] < 0.0005 1.64
High late 0.87 [0.67, 1.12] 0.275 0.81
a Model 1 adjusted for cohort, maternal smoking and maternal hypertensive disorde
b Model 2 adjusted for cohort, maternal smoking, maternal hypertensive disorders, ppopulation and SGA and LGA were determined from sex specific
growth curves [16].
Statistics
Data from two cohorts were pooled. Differences in maternal
and fetal characteristics between the cohorts were analyzed with
independent samples t-test for continuous variables and chi
squared test of independence with subsequent post hoc analyses
for categorical variables. Association between mHb at different
time points of pregnancy and perinatal outcomes was analyzed
using multinomial logistic regression (MLR). Odds ratios (OR) and
95% confidence intervals (95% CI) were recorded and p-values
according to Wald’s test that were below 0.0125 (0.05/4 tests) were
considered statistically significant. Association was analyzed
without adjustments (base model), with adjustment for cohort,
maternal smoking and maternal hypertensive disorders (model 1)
and with adjustment for cohort, maternal smoking, maternal
hypertensive disorders, pre-pregnancy BMI, SES, parity and
maternal age at delivery (model 2). Statistical analyses were
conducted using R software package version 3.5.0 [18].
Results
Characteristics of the sample population
Distribution of offspring sex, maternal age and parity were
similar between the cohorts (Table 1). Other maternal and fetal
characteristics changed within the 20 years between the cohort
initiations. Number of mothers with low mHb at any point of
pregnancy was lower in NFBC1966 than in NFBC1986 whereas
number of housewives was considerably higher in NFBC1966.
Furthermore, number of mothers with either gestational or chronic
hypertension was higher in NFBC1966.
Multinomial logistic regression for perinatal outcomes
As shown in Table 2, low mHb at late pregnancy associated with
increased risk of prematurity (fully adjusted OR (aOR) 1.60, 95% CI
[1.26, 2.02], p < 0.0005). Associations between mHb and SGA and
LGA are indicated in Table 3. Low mHb at early pregnancy
associated with decreased risk of SGA (aOR 0.73, 95% CI [0.58, 0.93],
p = 0.010) and high mHb at late pregnancy with increased risk of
SGA (aOR 1.29, 95% CI [1.07, 1.56], p = 0.009, Table 2). Low mHb at
early pregnancy associated with increased risk of LGA; however,
the association was not statistically significant after adjustment for
maternal cofactors. High mHb at early pregnancy associated with
decreased risk of LGA in fully adjusted model but not in other
models. Results are shown separately for each cohort in
Supplementary Table 1. To characterize spontaneous preterm
delivery and normotensive SGA, we conducted additional MLR
analyses for pregnancies without maternal hypertensive disorders, odds ratio; 95% CI, 95% confidence interval; p, p-value according to Wald’s test,
el 1a Model 2b
95% CI p OR 95% CI p
 [0.97, 1.56] 0.081 1.24 [0.97, 1.59] 0.079
 [0.86, 1.41] 0.437 1.18 [0.91, 1.52] 0.209
 [1.31, 2.05] < 0.0005 1.60 [1.26, 2.02] < 0.0005
 [0.61, 1.09] 0.166 0.83 [0.62, 1.13] 0.236
rs.
re-pregnancy BMI, maternal SES, parity and maternal age.
Table 3
Association between maternal hemoglobin during pregnancy and full-term small and large for gestational age (SGA and LGA, respectively). OR, odds ratio; 95% CI, 95%
confidence interval; p, p-value according to Wald’s test, significant when p < 0.0125.
Base model Model 1a Model 2b
Outcome mHb OR 95% CI p OR 95% CI p OR 95% CI p
SGA Low early 0.74 [0.61, 0.90] 0.003 0.75 [0.59, 0.94] 0.011 0.73 [0.58, 0.93] 0.010
High early 1.10 [0.93, 1.30] 0.280 1.07 [0.87, 1.31] 0.518 1.15 [0.93, 1.42] 0.199
Low late 0.88 [0.74, 1.06] 0.173 0.82 [0.67, 1.02] 0.073 0.84 [0.67, 1.05] 0.129
High late 1.29 [1.10, 1.50] 0.001 1.30 [1.09, 1.56] 0.004 1.29 [1.07, 1.56] 0.009
LGA Low early 1.23 [1.05, 1.44] 0.010 1.25 [1.05, 1.50] 0.013 1.23 [1.02, 1.49] 0.030
High early 0.95 [0.80, 1.14] 0.598 0.83 [0.68, 1.03] 0.086 0.72 [0.57, 0.91] 0.005
Low late 1.22 [1.04, 1.43] 0.014 1.25 [1.04, 1.50] 0.015 1.22 [1.01, 1.48] 0.039
High late 0.96 [0.81, 1.13] 0.605 0.93 [0.76, 1.12] 0.436 0.99 [0.81, 1.21] 0.915
a Model 1 adjusted for cohort, maternal smoking and maternal hypertensive disorders.
b Model 2 adjusted for cohort, maternal smoking, maternal hypertensive disorders, pre-pregnancy BMI, maternal SES, parity and maternal age.
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well as SGA (reviewed in [19]). As shown in Supplementary Table 2,
similar to main analyses, low mHb at late pregnancy was
associated with increased risk of spontaneous preterm delivery
(aOR 1.65, 95% CI [1.27, 2.15], p < 0.0005). High mHb at late
pregnancy was associated with increased risk of normotensive
full-term SGA in model 1 (OR 1.34, 95% CI [1.08,1.66], p = 0.009) and
borderline significant in other models.
Sensitivity analyses
As we do not have the exact gestational age at the last antenatal
visit for all mothers, we were not able to estimate the effect of exact
mHb measurement timing on the perinatal outcome. This is critical
specifically with the case of prematurity, because during normal
pregnancy, mHb decreases until 20 weeks of gestation and then
begins to increase around 30 weeks of gestation [20]. To confirm that
our results are not due to normal mHb change during pregnancy, we
conducted sensitivity analyses such as i) MLR of individuals with
available information about gestational age at last antenatal visit
(n = 7,281), ii) MLR of pregnancies with birth at 32 weeks of gestation
ormoreand iii)MLRof gestational age-adjustedlate pregnancymHb.
These analyses showed similar results with the main analyses
(Supplementary Tables 3–5). Association between prematurity and
low mHb at late pregnancy was not statistically significant when
gestational age at last antenatal visit was added to the models
(Supplementary Table 3). This is most likely due to lack of power
because only 45 preterm deliveries had the information about
gestational age at last antenatal visit and were included in the
gestational age at last antenatal visit-adjusted model.
Comment
The current study indicates that low mHb at late pregnancy is
associated with increased risk of preterm delivery and high mHb
with increased risk of full-term SGA. These results support the
previouslypublished concept of U-shaped association between mHb
concentration and the risk of adverse perinatal outcomes [7,21].
However, there are discrepancies between previous publications
with respect of this association. One problem related to the
generalization of the results from mHb studies concerns the
differences between study populations [22]. In low-income coun-
tries, the mHb level often relates to the poor nutritional status of the
mother contributing to adverse perinatal outcomes. In addition, the
prevalence of infectious diseases such as HIV and malaria is higher in
the developing countries, which adds further burden to maternal
health [5]. This socioeconomic and nutritional disparity may lead to
severe residual confounding in the analyses. Current study popula-
tion is located in Finland where standardized antenatal care system
and relatively high living standards induce smaller differences inenvironmental factors affecting the development of the fetus and yet
still, abnormal mHb was associated with prematurity and SGA.
Another issue varying between studies relates to the timing of
the mHb measurement during pregnancy. Level of mHb changes
naturally throughout the pregnancy and it may be critical for the
results whether the measurement occurs at early or late pregnancy
[20]. In the current study, we wanted to evaluate mHb at early and
late pregnancy to find out how they contribute to overall risk of
adverse perinatal outcomes. Our results indicate that abnormal
mHb measured at late pregnancy associates with increased risk of
prematurity and SGA. Fetus grows rapidly during the third
trimester when iron and other micronutrient demands are
specifically high [23]. Abnormal mHb may reflect insufficient
availability and/or delivery of nutrients to the fetus and specifically
at the end of pregnancy alter the rapid growth phase. It is safe to
assume that due to systematic antenatal care in Finland, if low
mHb was measured at the beginning of the pregnancy, it had been
attempted to increase by administration of iron supplements or
other medical actions. Interestingly, low mHb at the beginning of
pregnancy was in fact associated with decreased risk of SGA in
current study. In high-income countries, approximately 60% of the
pregnant women with low hemoglobin are estimated to be
amenable to iron supplementation [9]. Thus, the mothers with low
mHb at late pregnancy may be the ones that do not response to iron
supplementation and are at increased risk of preterm delivery in
the current study. We know that iron supplementation was
recommended already in 1960s for pregnant women to prevent
gestational anemia [8,24]; however, we do not have information
about its administration or iron status of the mother in the current
study to research this issue in more detail.
Further variation within mHb studies is added by varying
cutoffs for categorical variables of low and high mHb. WHO defines
anemia during pregnancy as mHb less than 110 g/l, which is widely
used cutoff for low mHb [9]. However, discussion about an
appropriate cutoff during pregnancy is ongoing as some studies
found association only with mHb levels below 100 g/l [25,26].
Furthermore, similar to previous studies located in Finland and
Sweden [22,27], the prevalence of anemia with the 110 g/l cutoff
was low in the current study, only approximately 4%. The earlier
Finnish study with more stringent cutoff of 100 g/l did not found
association between mHb and preterm delivery and SGA, which
may result from decreased statistical power due to low number of
mothers with “true anemia” [22]. To overcome this issue, we
decided to define lowest 10% of the mHb z values as low mHb and
highest 10% of the mHb z values as high mHb. These correspond to
cutoff values for low mHb of approximately 110 g/l in NFBC1966
and 117 g/l in NFCB1986. For high mHb, cutoff values were 135 g/l
and 140 g/l in NFBC1966 and NFBC1986, respectively. Z values were
calculated for each cohort and pregnancy time point separately,
thus the extremes of mHb are relative for the reference, not for the
48 J. Ronkainen et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 238 (2019) 44–48absolute mHb concentration that may differ throughout the
pregnancy.
The mechanism behind the association is unclear. Iron
deficiency may contribute to the restricted fetal growth and
prematurity through such mechanisms as increased maternal and
fetal stress, increased serum norepinephrine production and
oxidative damage to erythrocytes and fetoplacental unit (reviewed
in [28]). Mothers with low mHb show increased placental
vascularization suggesting earlier placental maturity, which may
contribute to increased risk of preterm delivery [29,30]. Low mHb
may cause chronic hypoxia which in turn may induce a stress-
response with increased placental corticotropin-releasing hor-
mone (CRH) production. During normal pregnancy, a rapid
increase in bioavailable CRH induces labor and if this occurs too
early, it may induce preterm delivery (28). High mHb, specifically
during late pregnancy may indicate incomplete hemodilution and
may lead to fetal hypoxia due to increased blood viscosity and
impairment of maternal-fetal exchange and contribute to the risk
of SGA [1]. Further studies located in high-income countries as well
as deeper mechanistic understanding are needed with respect of
association between mHb and fetal growth.
Strengths and weaknesses of the study
Large sample size in a homogenous population is major
strength of the current study. Universal antenatal care available
in Finland and high standard of living offer less variation in the
environmental factors affecting the intrauterine development of
the child. First limitation is that we do not have reliable
information about exact gestational age at mHb measurements
from all study subjects in the current study. The measurement
timing is specifically important when prematurity is assessed
because mHb begins to naturally increase after 30 weeks of
gestation. To overcome this, we conducted series of sensitivity
analyses that showed similar results as our main models indicating
that the association between low mHb at late pregnancy and
prematurity is not mediated by the timing of mHb measurement.
Other limitations relate to the lack of clinical measures of fetal
hypoxia and iron metabolism. Our data suggests that there may be
distinct outcomes depending on the mother’s responsiveness on
iron supplementation. The current study shows that both low and
high mHb may indicate increased risk for distress in the developing
child. Mechanistic studies are warranted to reveal the possible
causal influence of abnormal mHb on perinatal outcomes.
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